12 Leukemia Clinical Trials in Grand Rapids, MI (2026)

Q: How do I join a clinical trial in Grand Rapids?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Grand Rapids research site will contact you.

Recruiting Leukemia Studies in Grand Rapids

NCT05005403Recruiting

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues...

Grand Rapids, MIPHASE1694 participantsAbbVie

View Study Details

NCT07349537Recruiting

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or...

Grand Rapids, MIPHASE1574 participantsRevolution Medicines, Inc.

View Study Details

NCT05786924Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combin...

Grand Rapids, MIPHASE1554 participantsInstitut de Recherches Internationales Servier

View Study Details

NCT06128551Recruiting

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors....

Grand Rapids, MIPHASE1534 participantsRevolution Medicines, Inc.

View Study Details

NCT04811560Recruiting

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 Part 1 (Dose Escalation) and to determine the safety and tolerability at RP2D in Phase 1 ...

Grand Rapids, MIPHASE1420 participantsJanssen Research & Development, LLC

View Study Details

NCT07335497Recruiting

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) ...

Grand Rapids, MIPHASE1290 participantsCrescent Biopharma, Inc.

View Study Details

NCT07174583Recruiting

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC....

Grand Rapids, MIPHASE1262 participantsIDEAYA Biosciences

View Study Details

NCT07085091Recruiting

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors...

Grand Rapids, MIPHASE1170 participantsALX Oncology Inc.

View Study Details

NCT06969430Recruiting

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

The primary purpose of Phase 1 is to assess the doses studied under Phase 1 (Dose Escalation) Arm A and identify the recommended dose (RD) for further development (Dose optimization). The primary obj...

Grand Rapids, MIPHASE1134 participantsDebiopharm International SA

View Study Details

NCT05362773Recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have...

Grand Rapids, MIPHASE1130 participantsMacroGenics

View Study Details

NCT06714591Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia....

Grand Rapids, MIPHASE1120 participantsSystImmune Inc.

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

Grand Rapids, MIPHASE1114 participantsIpsen

View Study Details

About Leukemia Clinical Trials in Grand Rapids

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 12 leukemia clinical trials recruiting participants in Grand Rapids, MI. These studies are seeking a combined 3,996 participants. Research is being sponsored by AbbVie, Revolution Medicines, Inc., Institut de Recherches Internationales Servier and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Grand Rapids — FAQ

Are there leukemia clinical trials in Grand Rapids?

Yes, there are 12 leukemia clinical trials currently recruiting in Grand Rapids, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Grand Rapids?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Grand Rapids research site will contact you about next steps.

Are clinical trials in Grand Rapids free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Grand Rapids studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 12 active trials in Grand Rapids are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 17, 2026 from ClinicalTrials.gov